COMMUNIQUÉS West-GlobeNewswire

Merus et Biohaven annoncent une collaboration pour co-développer trois nouveaux programmes de CAM bispécifiques
13/01/2025
NEW HAVEN, Connecticut, et UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 13 janv. 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE : BHVN) et Merus N.V. (Nasdaq : MRUS) ont annoncé ce jour une collaboration de recherche et [...]
Correction: GUERBET : Financial agenda for 2025
13/01/2025
Financial agenda for 2025 Villepinte, 13 janvier 2025 : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. Publications [...]
Correction: GUERBET : Calendrier financier de l'exercice 2025
13/01/2025
Calendrier financier de l’exercice 2025 Villepinte, le 13 janvier 2025 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, publie son calendrier financier [...]
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
13/01/2025
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced the [...]
OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer
13/01/2025
OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer Nantes, France, le 13 janvier 2025, 18 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) [...]
Press release: Transparency Notification from Shareholders
13/01/2025
Transparency Notification from Shareholders Ghent, Belgium – 13 January 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of fluid overload in [...]
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
13/01/2025
- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types - Fully enrolled three major market Phase [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
13/01/2025
Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, January [...]
ProMIS Neurosciences Issues Letter to Shareholders
13/01/2025
CAMBRIDGE, Massachusetts, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics [...]
Baylor Genetics to Integrate with Epic Aura to Enhance Efficiency and Deliver Genetic Testing Results to Hospitals and Health Systems
13/01/2025
The company will be the first to integrate whole genome sequencing (WGS) into Epic's Aura platform, further advancing access to genetic insights for patients and providers in the neonatal and pediatric intensive care [...]
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
13/01/2025
This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 million Program progress and performance triggers $16.7 million [...]
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
13/01/2025
Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated [...]
NAYA Biosciences Announces Pricing of $9.5 Million Public Offering
13/01/2025
SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune [...]
Positron Corporation Engages Skyline Corporate Communications Group, LLC to Enhance Investor Relations and Financial Community Outreach
13/01/2025
Niagara Falls, NY, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission [...]
Avance Clinical Leads as the CRO of Choice for Early Phase Clinical Trials in Australia – Announced at Biotech Showcase 2025
13/01/2025
WAKE FOREST, N.C. and ADELAIDE, Australia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Avance Clinical , a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical [...]
HealthEquity Announces Record Year-End HSA Sales Outlook, Presentation at J.P. Morgan Healthcare Conference
13/01/2025
DRAPER, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced estimates of HSAs, HSA [...]
Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors
13/01/2025
PLAINVIEW, N.Y, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leader in human capital, information technology and MedTech, today announced new executive appointments to the Vaso management [...]
NeurAxis Inc. Issues Letter to Shareholders
13/01/2025
CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
13/01/2025
The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan. 13, 2025 (GLOBE [...]

Pages